XOMA (XOMA) Statistics

XOMA Corp, a biotech company, is engaged in the discovery, development, and manufacture of therapeutic antibodies. The company's stock, symbol XOMA, is traded on the NASDAQ. XOMA Corp has a market capitalization of $XXX million, with a price-to-earnings ratio of XX.XX. The stock's price-to-sales ratio is X.XX, indicating the company's strong revenue generation. XOMA Corp's enterprise value-to-EBITDA ratio stands at X.XX, highlighting its efficient use of capital. The company's profit margin is X.XX%, indicating its ability to generate profits from its operations. XOMA Corp has total debt of $XXX million, suggesting a moderate level of financial leverage. The company's gross profit is $XXX million, reflecting its ability to generate substantial revenue after deducting production costs. The CEO of XOMA Corp, Mr. [CEO Name], leads the company's strategic direction and oversees its operations.

XOMA Corp's stock performance has been compared to the sector average to gauge its relative strength. Based on recent data, XOMA Corp's stock has outperformed the sector by X% over the specified period. This suggests that the company has delivered superior returns to its investors compared to its peers. Additionally, XOMA Corp's revenue per share indicates the amount of revenue generated for each outstanding share of the company's stock. With revenue per share of $X.XX, XOMA Corp demonstrates its ability to efficiently generate revenue and create value for shareholders.